viewQ BioMed Inc.

Q BioMed's bone pain drug Strontium89 sees Medicare reimbursement rate upped

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the Centers for Medicare and Medicaid Services (CMS) updated the reimbursement rate for its metastatic bone pain drug Strontium89, making it more easily available to Medicare patients.

Corin says with the CMS update, all Medicare providers are now able to be reimbursed appropriately for providing Strontium89 treatment, giving Q BioMed the ability to engage with hospitals and providers throughout the US and a potential increase in the use of Strontium89.

Quick facts: Q BioMed Inc.

Price: 1.1 USD

Market: OTCQB
Market Cap: $28.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...


Q BioMed forms five year contract with the US DoD and Veterans Affairs for...

Q BioMed Inc (OTCQB:QBIO) Chief Commercial Officer Kristin Keller tells Proactive the group has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiaries. The biotech has inked a...

3 days, 21 hours ago

2 min read